These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
100 related articles for article (PubMed ID: 25710543)
1. Development of a phenotypic high-content assay to identify pharmacoperone drugs for the treatment of primary hyperoxaluria type 1 by high-throughput screening. Madoux F; Janovick JA; Smithson D; Fargue S; Danpure CJ; Scampavia L; Chen YT; Spicer TP; Conn PM Assay Drug Dev Technol; 2015; 13(1):16-24. PubMed ID: 25710543 [TBL] [Abstract][Full Text] [Related]
2. Drug Library Screening for the Identification of Ionophores That Correct the Mistrafficking Disorder Associated with Oxalosis Kidney Disease. Hou S; Madoux F; Scampavia L; Janovick JA; Conn PM; Spicer TP SLAS Discov; 2017 Aug; 22(7):887-896. PubMed ID: 28346094 [TBL] [Abstract][Full Text] [Related]
3. Re: Development of a Phenotypic High-Content Assay to Identify Pharmacoperone Drugs for the Treatment of Primary Hyperoxaluria Type 1 by High-Throughput Screening. Assimos DG J Urol; 2015 Oct; 194(4):1015. PubMed ID: 26382786 [No Abstract] [Full Text] [Related]
4. Translation inhibition corrects aberrant localization of mutant alanine-glyoxylate aminotransferase: possible therapeutic approach for hyperoxaluria. Belostotsky R; Lyakhovetsky R; Sherman MY; Shkedy F; Tzvi-Behr S; Bar R; Hoppe B; Reusch B; Beck BB; Frishberg Y J Mol Med (Berl); 2018 Jul; 96(7):621-630. PubMed ID: 29777253 [TBL] [Abstract][Full Text] [Related]
5. Multiple mechanisms of action of pyridoxine in primary hyperoxaluria type 1. Fargue S; Rumsby G; Danpure CJ Biochim Biophys Acta; 2013 Oct; 1832(10):1776-83. PubMed ID: 23597595 [TBL] [Abstract][Full Text] [Related]
6. Pharmacologic rescue of an enzyme-trafficking defect in primary hyperoxaluria 1. Miyata N; Steffen J; Johnson ME; Fargue S; Danpure CJ; Koehler CM Proc Natl Acad Sci U S A; 2014 Oct; 111(40):14406-11. PubMed ID: 25237136 [TBL] [Abstract][Full Text] [Related]
7. Transitioning pharmacoperones to therapeutic use: in vivo proof-of-principle and design of high throughput screens. Conn PM; Smithson DC; Hodder PS; Stewart MD; Behringer RR; Smith E; Ulloa-Aguirre A; Janovick JA Pharmacol Res; 2014 May; 83():38-51. PubMed ID: 24373832 [TBL] [Abstract][Full Text] [Related]
8. Integrated in vitro-in silico screening strategy for the discovery of antibacterial compounds. Nybond S; Ghemtio L; Nawrot DA; Karp M; Xhaard H; Tammela P Assay Drug Dev Technol; 2015; 13(1):25-33. PubMed ID: 25710544 [TBL] [Abstract][Full Text] [Related]
9. Structural and functional insights on the roles of molecular chaperones in the mistargeting and aggregation phenotypes associated with primary hyperoxaluria type I. Fernández-Higuero JÁ; Betancor-Fernández I; Mesa-Torres N; Muga A; Salido E; Pey AL Adv Protein Chem Struct Biol; 2019; 114():119-152. PubMed ID: 30635080 [TBL] [Abstract][Full Text] [Related]
10. High-throughput screening using beta-lactamase reporter-gene technology for identification of low-molecular-weight antagonists of the human gonadotropin releasing hormone receptor. Oosterom J; van Doornmalen EJ; Lobregt S; Blomenröhr M; Zaman GJ Assay Drug Dev Technol; 2005 Apr; 3(2):143-54. PubMed ID: 15871689 [TBL] [Abstract][Full Text] [Related]
11. A miniaturized homogenous assay of mitochondrial membrane potential. Vongs A; Solly KJ; Kiss L; Macneil DJ; Rosenblum CI Assay Drug Dev Technol; 2011 Aug; 9(4):373-81. PubMed ID: 21294696 [TBL] [Abstract][Full Text] [Related]
13. AlphaLISA-based high-throughput screening assay to measure levels of soluble amyloid precursor protein α. Wang H; Nefzi A; Fields GB; Lakshmana MK; Minond D Anal Biochem; 2014 Aug; 459():24-30. PubMed ID: 24857774 [TBL] [Abstract][Full Text] [Related]
14. An efficient method for the detection and elimination of systematic error in high-throughput screening. Makarenkov V; Zentilli P; Kevorkov D; Gagarin A; Malo N; Nadon R Bioinformatics; 2007 Jul; 23(13):1648-57. PubMed ID: 17463024 [TBL] [Abstract][Full Text] [Related]
15. The N-terminal extension is essential for the formation of the active dimeric structure of liver peroxisomal alanine:glyoxylate aminotransferase. Montioli R; Fargue S; Lewin J; Zamparelli C; Danpure CJ; Borri Voltattorni C; Cellini B Int J Biochem Cell Biol; 2012 Mar; 44(3):536-46. PubMed ID: 22198249 [TBL] [Abstract][Full Text] [Related]
16. High throughput cell-based assay for identification of glycolate oxidase inhibitors as a potential treatment for Primary Hyperoxaluria Type 1. Wang M; Xu M; Long Y; Fargue S; Southall N; Hu X; McKew JC; Danpure CJ; Zheng W Sci Rep; 2016 Sep; 6():34060. PubMed ID: 27670739 [TBL] [Abstract][Full Text] [Related]
17. The molecular basis of alanine: glyoxylate aminotransferase mistargeting: the most common single cause of primary hyperoxaluria type 1. Danpure CJ J Nephrol; 1998; 11 Suppl 1():8-12. PubMed ID: 9604801 [TBL] [Abstract][Full Text] [Related]
18. Implications of genotype and enzyme phenotype in pyridoxine response of patients with type I primary hyperoxaluria. Monico CG; Olson JB; Milliner DS Am J Nephrol; 2005; 25(2):183-8. PubMed ID: 15849466 [TBL] [Abstract][Full Text] [Related]
19. A one-day, dispense-only IP-One HTRF assay for high-throughput screening of Galphaq protein-coupled receptors: towards cells as reagents. Bergsdorf C; Kropp-Goerkis C; Kaehler I; Ketscher L; Boemer U; Parczyk K; Bader B Assay Drug Dev Technol; 2008 Feb; 6(1):39-53. PubMed ID: 18315499 [TBL] [Abstract][Full Text] [Related]
20. Differentiation and visualization of diverse cellular phenotypic responses in primary high-content screening. Kümmel A; Selzer P; Siebert D; Schmidt I; Reinhardt J; Götte M; Ibig-Rehm Y; Parker CN; Gabriel D J Biomol Screen; 2012 Jul; 17(6):843-9. PubMed ID: 22396475 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]